185 related articles for article (PubMed ID: 27916761)
1. CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration.
Ogushi N; Sasaki K; Shimoda M
J Vet Med Sci; 2017 Feb; 79(2):320-327. PubMed ID: 27916761
[TBL] [Abstract][Full Text] [Related]
2. Effect of cyclosporin on distribution of methotrexate into the brain of rats.
Ogushi N; Sasaki K; Shimoda M
J Vet Med Sci; 2015 Sep; 77(9):1171-3. PubMed ID: 25947324
[TBL] [Abstract][Full Text] [Related]
3. Effects of leucovorin (folinic acid) in the methotrexate-treated rat brain.
Ogushi N; Sasaki K; Shimoda M
J Vet Med Sci; 2018 May; 80(5):760-765. PubMed ID: 29607891
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-bestatin interaction: involvement of P-glycoprotein and organic anion transporters in rats.
Zhu Y; Meng Q; Wang C; Liu Q; Huo X; Zhang A; Sun P; Sun H; Li H; Liu K
Int J Pharm; 2014 Apr; 465(1-2):368-77. PubMed ID: 24530518
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
Glantz MJ; Cole BF; Recht L; Akerley W; Mills P; Saris S; Hochberg F; Calabresi P; Egorin MJ
J Clin Oncol; 1998 Apr; 16(4):1561-7. PubMed ID: 9552066
[TBL] [Abstract][Full Text] [Related]
6. Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123.
Pavek P; Staud F; Fendrich Z; Sklenarova H; Libra A; Novotna M; Kopecky M; Nobilis M; Semecky V
J Pharmacol Exp Ther; 2003 Jun; 305(3):1239-50. PubMed ID: 12626638
[TBL] [Abstract][Full Text] [Related]
7. Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry.
Guo P; Wang X; Liu L; Belinsky MG; Kruh GD; Gallo JM
J Pharm Biomed Anal; 2007 Apr; 43(5):1789-95. PubMed ID: 17289326
[TBL] [Abstract][Full Text] [Related]
8. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Chemother Pharmacol; 1996; 38(6):499-507. PubMed ID: 8823490
[TBL] [Abstract][Full Text] [Related]
9. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
Yuan SH; Ge WH; Huo J; Wang XH
Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
[TBL] [Abstract][Full Text] [Related]
10. Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments.
Balthasar JP; Fung HL
J Pharm Sci; 1996 Oct; 85(10):1035-43. PubMed ID: 8897267
[TBL] [Abstract][Full Text] [Related]
11. Variability of oral bioavailability for low dose methotrexate in rats.
Kuroda T; Namba K; Torimaru T; Yamamoto S; Akahori M
Eur J Drug Metab Pharmacokinet; 2001; 26(4):227-34. PubMed ID: 11808864
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of methotrexate in systemic tissues after intrathecal administration.
Bleyer WA; Nelson JA; Kamen BA
J Pediatr Hematol Oncol; 1997; 19(6):530-2. PubMed ID: 9407940
[TBL] [Abstract][Full Text] [Related]
13. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
Kong SY; Tang GT; Pei YY; Jiang YY
Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
16. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats.
Liu H; Xu X; Yang Z; Deng Y; Liu X; Xie L
Brain Res; 2006 Dec; 1123(1):245-52. PubMed ID: 17074306
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats.
Park JM; Moon CH; Lee MG
Res Commun Mol Pathol Pharmacol; 1996 Sep; 93(3):353-62. PubMed ID: 8896046
[TBL] [Abstract][Full Text] [Related]
18. Neuropharmacokinetic evaluation of methotrexate-loaded chitosan nanogels.
Azadi A; Rouini MR; Hamidi M
Int J Biol Macromol; 2015 Aug; 79():326-35. PubMed ID: 25959975
[TBL] [Abstract][Full Text] [Related]
19. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Sane R; Wu SP; Zhang R; Gallo JM
Drug Metab Dispos; 2014 Apr; 42(4):537-40. PubMed ID: 24464805
[TBL] [Abstract][Full Text] [Related]
20. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats.
Wang F; Jiang X; Lu W
Int J Pharm; 2003 Sep; 263(1-2):1-7. PubMed ID: 12954175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
